A systematic assessment of robustness in CNS safety pharmacology
Maria Reiber, Helen Stirling, Tim P. Ahuis, Washington Arias, Katharina Aulehner, Ute Dreßler, Martien J. H. Kas, Johanna Kela, Kimberly Kerker, Tarja Kuosmanen, Helga Lorenz, Alexander T. Pennington, Eva-Lotta von Rüden, Heike Schauerte, Isabel...
The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
Heterozygous mutations in the GBA1 gene – encoding lysosomal glucocerebrosidase (GCase) – are the most common genetic risk factors for...
Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake
Bassem F. El-Khodor, Karma James, Qing Chang, Wei Zhang, Yvette R. Loiselle, Chinmayee Panda & Taleen Hanania Nutritional Neuroscience. 2022...
Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia
E. Leahy, M. Varney and D. Brunner SEP-363856, a novel, first-in-class drug treatment being developed by Sunovion Pharmaceuticals, showed robust...
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex
Theilmann, et. al, Neuropharmacology. 2020 Theilmann, W, Gericke, B,Schidlitzki, A, Anjum, S, Borsdorf, S, Harries, T, Roberds, S.L.,Aguiar, D, Brunner,...